Labcorp Holdings INC Form 4 insider transactions

Labcorp Holdings Inc. Director Peter M. Neupert was granted 773 Restricted Stock Units, vesting fully on February 10, 2027.

Labcorp Holdings Inc. director Kirsten M. Kliphouse was granted 773 restricted stock units, vesting fully on February 10, 2027.

Labcorp Holdings Inc. Director Jeffrey A. Davis acquired 773 Restricted Stock Units, bringing his total beneficial ownership to 1,670 RSUs.

Labcorp Holdings Inc. Director Victor Bulto Carulla was granted 773 Restricted Stock Units, vesting in February 2027.

Labcorp Holdings Inc. Director Kerrii B. Anderson was granted 773 Restricted Stock Units, vesting in February 2027.

Labcorp's Chief Financial Officer, Julia Aijun Wang, reported the vesting of restricted stock units and subsequent sale of shares for tax obligations.

Labcorp Holdings Inc. EVP Brian J. Caveney reported multiple transactions involving common stock and Restricted Stock Units, including acquisitions from RSU vesting and dispositions for tax withholding.

Labcorp Holdings Inc. EVP, CIO & CTO Akinbolade Oyegunwa increased direct common stock holdings following the vesting and tax-related disposition of Restricted Stock Units.

Labcorp's President and CEO, Adam H. Schechter, reported the exercise and vesting of Restricted Stock Units and subsequent tax-related stock dispositions.

Labcorp's SVP and Chief Accounting Officer, Peter J. Wilkinson, reported recent acquisitions of common stock through RSU vesting and subsequent dispositions for tax obligations.

Labcorp Holdings Inc. EVP Mark S. Schroeder disclosed recent acquisitions of common stock from Restricted Stock Unit vesting and subsequent dispositions for tax obligations.

Labcorp's EVP of Corporate Affairs, Sandra D. van der Vaart, reported recent acquisitions and dispositions of common stock related to Restricted Stock Unit vesting and tax withholdings.

Labcorp's EVP of Diagnostics, Bryan T. Vaughn, converted restricted stock units into common stock and subsequently sold shares to cover tax obligations.

Jonathan C. Meltzer, EVP of Operations at Labcorp Holdings Inc., reported the vesting of Restricted Stock Units and subsequent sales, including tax withholdings, as part of a pre-arranged 10b5-1 plan.

Labcorp's EVP, Chief Legal Officer, Kathryn W. Kyle, reported the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Labcorp's EVP and CHRO, Anita Z. Graham, reported the vesting of restricted stock units and subsequent tax-related stock dispositions.

Labcorp Holdings Inc.'s EVP, Chief Marketing Officer, Amy B. Summy, reported the vesting and conversion of restricted stock units and subsequent tax-related stock dispositions.

Megan D. Bailey, EVP and President of Central Labs & International at Labcorp, reported the acquisition and disposition of common stock related to RSU vesting and tax withholding.

Labcorp Holdings Inc. Director Victor Bulto Carulla was granted 136 Restricted Stock Units, aligning his interests with shareholders.

Labcorp's President and CEO, Adam H. Schechter, sold 5,745 shares of common stock for $262.75 per share on November 11, 2025, under a pre-arranged 10b5-1 plan.

Megan D. Bailey, EVP and President of Central Labs & International at Labcorp, exercised Restricted Stock Units and sold shares to cover tax obligations.

Labcorp's EVP, CIO & CTO, Akinbolade Oyegunwa, reported the acquisition of shares from RSU vesting and subsequent sale for tax obligations.

Labcorp Holdings Inc. Director Richelle P. Parham sold 7,009 shares of common stock for approximately $1.78 million.

Labcorp's EVP and Chief Legal Officer, Sandra D. van der Vaart, reported exercising stock options and selling shares on August 13, 2025.

Labcorp Holdings Inc. President and CEO Adam H. Schechter reported a planned sale of 5,643 shares of common stock for $266.78 per share, scheduled for August 11, 2025, under a Rule 10b5-1 plan.

A director at Labcorp Holdings Inc. has filed a Form 4 indicating a pre-planned sale of 2,000 shares of common stock scheduled for July 30, 2025.

Peter J. Wilkinson, Labcorp's SVP and Chief Accounting Officer, sold 202 shares of common stock on July 29, 2025, under a Rule 10b5-1 trading plan.

Labcorp Holdings Inc. Director Kerrii B. Anderson has filed a Form 4 disclosing a planned sale of 3,500 shares of common stock on July 24, 2025, at a price of $280 per share, executed under a Rule 10b5-1 trading plan.

Labcorp Holdings Inc. Director Kerrii B. Anderson sold 3,500 shares of common stock for $280 per share, totaling $980,000, under a Rule 10b5-1 trading plan.

Labcorp Holdings Inc. Director Kerrii B. Anderson has filed a Form 4 disclosing a pre-planned sale of 500 shares of common stock at $265 per share, scheduled for July 1, 2025, under a Rule 10b5-1 plan.